457 related articles for article (PubMed ID: 18480833)
21. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
22. A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature.
Misialek MJ; Pechet L
Acta Haematol; 1997; 98(4):221-7. PubMed ID: 9401502
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
24. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Tefferi A; Skoda R; Vardiman JW
Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
[TBL] [Abstract][Full Text] [Related]
26. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
27. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
Harada H
Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
[No Abstract] [Full Text] [Related]
28. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
29. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
30. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J; Hyjek E
Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
[TBL] [Abstract][Full Text] [Related]
31. Mixed myeloproliferative and myelodysplastic disorders.
Emanuel PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):9-12. PubMed ID: 20425383
[TBL] [Abstract][Full Text] [Related]
32. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
33. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Tefferi A; Gilliland G
Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
35. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Mughal TI; Cross NC; Padron E; Tiu RV; Savona M; Malcovati L; Tibes R; Komrokji RS; Kiladjian JJ; Garcia-Manero G; Orazi A; Mesa R; Maciejewski JP; Fenaux P; Itzykson R; Mufti G; Solary E; List AF
Haematologica; 2015 Sep; 100(9):1117-30. PubMed ID: 26341525
[TBL] [Abstract][Full Text] [Related]
36. Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Tefferi A
Leuk Lymphoma; 2008 Jul; 49(7):1225-7. PubMed ID: 18604709
[No Abstract] [Full Text] [Related]
37. Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
[TBL] [Abstract][Full Text] [Related]
38. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Smith BN; Savona M; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
Occhipinti E; Correa H; Yu L; Craver R
Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
[TBL] [Abstract][Full Text] [Related]
40. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]